Fundz

Kymera Therapeutics Raises $602 Million in Follow-On Offering

PUBLIC · KYMRDec 10, 2025

Amount Raised

$602 Million

Round Type

Post-IPO Equity

CambridgeBiotechnologyTherapeuticsPharmaceuticalBiopharma

Investors

Wells Fargo Securities, LLCGuggenheim Securities, LLCStifel, Nicolaus & Company, IncorporatedJefferies LLCJ.P. Morgan Securities LLCMorgan Stanley & Co. LLC

Description

On December 9, 2025, Kymera Therapeutics, Inc. announced its entry into an underwriting agreement to issue and sell 7,000,000 shares of its common stock. Priced at $86.00 per share, the offering is expected to raise approximately $602 million. The company has granted underwriters a 30-day option to purchase additional shares, potentially increasing the total amount raised.

Who else raised in Therapeutics and Pharmaceutical around the same time

Companies in the same sectors as Kymera Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Os Therapies raised $3.5M on January 14, 2026.
  • Parabilis Medicines raised $305M (Series F) on January 8, 2026.
  • CASI Pharmaceuticals raised $5M on December 27, 2025.
  • Terns Pharmaceuticals raised $196M (Post-IPO Equity) on December 11, 2025.
  • Citius Oncology raised $18M (Funding Round) on December 9, 2025.
  • Navega Therapeutics raised $1.3M (Seed) on January 2, 2026.

Who to call at Kymera Therapeutics, and when

A new round usually means Kymera Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Kymera Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Kymera Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Kymera Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Kymera Therapeutics

Location

Cambridge, Massachusetts, United States

About

Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Kymera Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsJaclyn K., Talent Acquisition Partner hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Kymera Therapeutics's next move

See what Strategic adds

Kymera Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.